Market Overview

EXACT Sciences Building A Better Screening Test - Initiating With A Buy And $10 Target


According to Auriga, EXACT Sciences Corp. (NASDAQ: EXAS) is building a better screening test and initiating with a Buy and $10 target.

Auriga reported that EXAS is developing Cologuard, a stool-based test for Colorectal
Cancer (CRC) screening, a potential $1 billion-plus market opportunity. “Clinical data to date has been impressive, demonstrating 85% sensitivity for cancer and 64% sensitivity for pre-cancer –putting Cologuard among the highest sensitivity and specificity screening tests on the market. EXAS continues to improve performance attributes, and we expect the locked assay to demonstrate 85% to 90% sensitivity for cancer and 64% sensitivity for pre-cancer in a large, prospective 10,000 patient clinical trial (3Q11 start). Putting these detection rates into a convenient, noninvasive platform, should fit well within the CRC screening market and enable EXAS to ultimately capture 30% of the estimated 12 million annual stool screens.”

EXACT Sciences closed yesterday at $5.43.

Posted-In: Auriga EXACT SciencesAnalyst Color Analyst Ratings


Related Articles (CRC + EXAS)

View Comments and Join the Discussion!

Latest Ratings

WEEDCantor FitzgeraldMaintains18.9
TGTXCantor FitzgeraldMaintains19.0
SPLKCleveland ResearchDowngrades
IQVWolfe ResearchUpgrades
PRAHWolfe ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Gold Pushing Record Highs

Daily Sound Bites: EU Rehn Makes Mixed Comments About Spain, Portugal